Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, three-way crossover, Phase 1 trial to quantitatively assess any effects of IV difelikefalin (CR845) on respiratory drive after bolus infusion in healthy volunteers

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled, three-way crossover, Phase 1 trial to quantitatively assess any effects of IV difelikefalin (CR845) on respiratory drive after bolus infusion in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pain; Pruritus
  • Focus Adverse reactions

    • Most Recent Events

    • 15 Mar 2018 According to a Cara Therapeutics media release, the company presented clinical data on the respiratory effects of I.V. CR845 from this trial at ANESTHESIOLOGY 2017, the American Society of Anesthesiologists annual meeting (in Oct 2017).
    • 24 Apr 2017 Data will be presented as part of the Journal Anesthesiology Symposium at the American Society of Anesthesiology (ASA) Annual Meeting, as reported in a Cara Therapeutics media release.
    • 24 Apr 2017 Summary results published in the Cara Therapeutics Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top